Tag:
Cornerstone Therapeutics
Latest Headlines
Latest Headlines
Cornerstone earns $75M licensing pact
Winston-Salem, NC-based Targacept has inked a $75 million licensing pact for Cornerstone Therapeutics' patents and preclinical programs that target nicotinic receptors. But in keeping with the
FDA wants precaution on Singulair, sister meds
FDA wants some allergy and asthma drugs to come with a new warning of potential psychiatric problems. In an announcement Friday, the agency said it had asked drugmakers to add cautionary language to
Chiesi grabs majority stake in Cornerstone
Italy's Chiesi Farmaceutici will buy a 51 percent stake in Cornerstone Therapeutics, a respiratory drug developer, in a deal valued at $70 million. Investors quickly signalled their disapproval of
